Showing 1 to 10 of 36 Clinical Trials
|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
MK-2140-006 NCT05458297  Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma |
Dr. Sarit Assouline Edrian Gabrielle Bumanlag 514-840-8222 poste 23638 |
|
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
MK-1026-003 NCT04728893 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Nawel Mechtouf 514-252-3400 poste 4681 |
|
A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCIC GEC LY.17 NCT02436707 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non-Hodgkin's Lymphoma |
Dr. Stéphane Doucet Chantal Gosselin 514-890-8000 poste 24892 |
|
A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCIC GEC LY.17 NCT02436707 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Non-Hodgkin's Lymphoma |
Dr. Jean-François Larouche Marie-Claude Bourgeois 418-649-0252 poste 63161 |
|
A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases
EBV-TCL-01 NCT02580539 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Non-Hodgkin's Lymphoma |
Dr. Jean-Sébastien Delisle Stéphanie Thiant 514-252-3400 poste 4681 |
|
Un registre de données cliniques et paracliniques, incluant une banque de tissus biologiques, de patients atteints d’un lymphome (Registre des lymphomes)
HMR-LYM001 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Michel-Olivier Gratton 514-252-3400 poste 2397 |
|
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma
TAC01-CD19-01 NCT03880279 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Michel-Olivier Gratton 514-252-3400 poste 2397 |
|
A Phase 2, Open-label, Single Arm, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 (Lisocabtagene Maraleucel) in Adult Subjects With High-risk, Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
TRANSCEND FL NCT04245839 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Olivier Cormier 514-252-3400 poste 5966 |
|
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
VT3996-202 NCT05011058 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Julie Trinh Lu 514-252-3400 poste 3336 |
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
InMIND (INCMOR 0208-301) NCT04680052 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Nawel Mechtouf 514-252-3400 poste 4681 |
Groupe d'étude en oncologie du Québec